Objective: Giant cell arteritis (GCA) is commonly known for its clinical presentation of temporal arteritis. However, GCA affects large arteries, predominantly the aorta and its proximal branches, in up to 75% of cases. We describe the clinical presentation and diagnostic test results of patients with large-vessel GCA.
Methods: Case description of 11 patients with large-vessel GCA diagnosed consecutively in our hospital.
Results: The clinical presentation of large-vessel GCA is highly variable, from systemic inflammation to aortic rupture. Imaging shows variable abnormalities, but 18-fluorodeoxyglucose positron-emission-tomography (18-FDG PET) seems to be a sensitive and reasonably specific diagnostic test for large-vessel GCA.
Conclusion: Large-vessel GCA is a clinically heterogeneous condition. 18-FDG PET should be considered in the diagnostic work-up of suspected cases. Since this disorder has a high complication rate, and is responsive to treatment with corticosteroids, a high level of clinical suspicion is warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2008.04.054 | DOI Listing |
J Surg Res
January 2025
Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri.
Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.
View Article and Find Full Text PDFCancer Treat Rev
January 2025
Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Electronic address:
Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.
View Article and Find Full Text PDFClin Oncol (R Coll Radiol)
December 2024
Faculty of Medicine and Health Sciences, University of Antwerp, Prinsstraat 13, 2000, Antwerp, Belgium; Department of Radiation Oncology, Iridium Netwerk, Oosterveldlaan 22, 2610, Antwerp, Belgium. Electronic address:
Aim: Tumour-infiltrating lymphocytes (TILs) represent a promising cancer biomarker. Different TILs, including CD8+, CD4+, CD3+, and FOXP3+, have been associated with clinical outcomes. However, data are lacking regarding the value of TILs for patients receiving radiation therapy (RT).
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Internal Medicine, Division of Hematology and Oncology, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Rationale: Aggressive angiomyxoma (AAM) is an exceptionally rare mesenchymal tumor that predominantly manifests in the female genital organs during the reproductive age. Its rarity alone makes it a fascinating subject for study. The diagnosis of AAM necessitates differentiation from other benign or mesenchymal tumors and can be confirmed through immunohistochemistry (IHC) staining.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, PR China.
Rationale: Bilateral gluteus medius contractures in adults are rare in clinical practice, with only a few cases reported. These contractures may result from repeated intramuscular injections during childhood. Understanding the clinical manifestations, diagnostic process, treatment, and outcomes can provide insights into effective management strategies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!